The trial of the PD-1 inhibitor nivolumab as a first-line treatment in advanced hepatocellular carcinoma (HCC) did not meet its overall survival endpoint but showed ‘clinically meaningful’ efficacy and safety benefits, an expert has told ESMO 2019 congress. Presenting data from the phase III CheckMate 459 trial in a late breaking session, Dr Thomas Yau, ...
Immunotherapy has potential as first line treatment in HCC: CheckMate 459
By Nicola Garrett
28 Sep 2019